Laura Roca-Alonso
Direttore operativo presso E-THERAPEUTICS PLC
Profilo
Laura Roca-Alonso is currently the Chief Operating & Business Officer at e-Therapeutics Plc.
Prior to this, she held the position of Director-Business Development at Gyroscope Therapeutics Ltd.
From 2004 to 2019, she served as the VP & Head-Corporate Development at Silence Therapeutics Plc.
Dr. Roca-Alonso holds a doctorate degree from Imperial College London, a graduate degree from University College London, and an undergraduate degree from Autonomous University of Barcelona.
Posizioni attive di Laura Roca-Alonso
| Società | Posizione | Inizio |
|---|---|---|
| E-THERAPEUTICS PLC | Direttore operativo | 02/04/2020 |
Precedenti posizioni note di Laura Roca-Alonso
| Società | Posizione | Fine |
|---|---|---|
| SILENCE THERAPEUTICS PLC | Corporate Officer/Principal | 01/01/2019 |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Corporate Officer/Principal | - |
Formazione di Laura Roca-Alonso
| Imperial College London | Doctorate Degree |
| Autonomous University of Barcelona | Undergraduate Degree |
| University College London | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| E-THERAPEUTICS PLC | Health Technology |
| SILENCE THERAPEUTICS PLC | Commercial Services |
| Aziende private | 1 |
|---|---|
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Laura Roca-Alonso
